Clinical trials: Benign Prostatic Hyperplasia
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Clinical study to examine the safety, tolerability and efficacy of long-term combination therapy of tamsulosin and solifenacin in the treatment of males with lower urinary tract symptoms (LUTS) associated with benign prostatic…
- Trial name
- Neptune II (NCT01021332)
- Testing
- tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg), tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
- Where
- 70 sites in Austria, Belarus and 9 more
- Volunteers
- 1,067 people
- Sponsor
- Astellas Pharma Europe B.V.
Benign Prostatic Hyperplasia
Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men
The primary purpose of this clinical trial is to evaluate the change in the International Prostate Symptom Score (IPSS) total score from the beginning of the study to the end of the study for subjects randomized to tadalafil 5mg…
- Trial name
- NCT00540124
- Testing
- Tadalafil, Tamsulosin
- Where
- 5 sites in South Korea
- Volunteers
- 151 people
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia
Prospective Sexual Function Study for BPH Subjects
This is an European double-blind, placebo controlled parallel group comparison of DUODART (fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg, one capsule daily) and placebo.
- Trial name
- NCT01777269
- Testing
- Dutasteride plus tamsulosin
- Where
- 67 sites in Australia, France and 5 more
- Volunteers
- 489 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia
Open-label, 6 month-treatment with the IP in all subjects. - Sample size: A total of 90 subjects will be enrolled so that among them at least 57 will complete the 6-month treatment period and evaluable for analysis.
- Trial name
- FDC114785 (NCT01673490)
- Testing
- Dutasteride/Tamsulosin
- Where
- Vietnam
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia
The purpose of this study was to determine the safety and effectiveness of different doses of botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT00284518
- Testing
- botulinum toxin Type A, normal saline
- Where
- 11 sites in Australia, Austria and 9 more
- Volunteers
- 380 people
- Sponsor
- Allergan
Prostatic Hyperplasia
Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia
The purpose of this study was to determine whether the daily consumption of decaffeinated green tea catechins (Polyphenon E®) for 1 year reduces the rate of progression to prostate cancer (PCa) in men diagnosed with HGPIN or…
- Trial name
- NCT00596011
- Testing
- Polyphenon E
- Where
- 10 sites in United States
- Volunteers
- 97 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Overactive Bladder
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
- Trial name
- NCT02656173
- Testing
- Mirabegron, Tamsulosin
- Where
- 58 sites in Japan, South Korea
- Volunteers
- 568 people
- Sponsor
- Astellas Pharma Inc
Prostatic Hyperplasia, Benign Prostatic Hyperplasia
Rezum I Pilot Study for Benign Prostatic Hyperplasia
Evaluate the safety and efficacy of the Rezum System for the treatment of BPH
- Conditions
- Prostatic Hyperplasia, Benign Prostatic Hyperplasia, Adenoma, Prostatic, Prostatic Adenoma
- Trial name
- Rezum Pilot (NCT02943070)
- Testing
- Rezum System
- Where
- 3 sites in Czechia, Dominican Republic and 1 more
- Volunteers
- 50 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia (BPH)
Study of Median Lobe Prostatic UroLift Procedure
The purpose of this study is to evaluate the safety and effectiveness of using UroLift in subjects with a prostatic median lobe enlargement due to benign prostatic hyperplasia (BPH).
- Trial name
- NCT02625545
- Testing
- UroLift System procedure
- Volunteers
- 45 people
- Sponsor
- NeoTract, Inc.
Benign Prostatic Hyperplasia
A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
This is a 24 week study evaluating the effects of botulinum toxin Type A on semen quality in patients with signs and symptoms of Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT00894517
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Allergan
Benign Prostatic Hyperplasia
Optilume™ BPH Catheter System in Men With Symptomatic BPH
PINNACLE is a prospective, multi-center, randomized control clinical trial to establish the safety and efficacy of the Optilume™ BPH Catheter System in the treatment of benign prostatic hyperplasia (BPH)
- Trial name
- PINNACLE (NCT04131907)
- Testing
- Optilume BPH Catheter System
- Where
- 21 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- Urotronic Inc.
Benign Prostatic Hyperplasia
Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System vs TURP for the Treatment of BPH
The study compares procedural and post procedural outcomes for photoselective vaporization of the prostate (PVP) and transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms due to benign…
- Trial name
- NCT01218672
- Testing
- Photoselective Vaporization of the Prostate, Transurethral Resection of the Prostate
- Where
- 29 sites in Austria, Belgium and 7 more
- Volunteers
- 291 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
A Clinical Trial Comparing Laser TURP With and Without Dutasteride.
The purpose of this research study is to determine if the study drug Dutasteride taken before and after Laser TURP(Transurethral Resection of the Prostate), can provide effective and safe, long term improvement of lower urinary…
- Trial name
- NCT00431626
- Testing
- Dutasteride (Avodart)
- Volunteers
- 4 people
- Sponsor
- Northwestern University
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Deprescribing Tamsulosin in Older Men
This is a pilot 12-week randomized, placebo-controlled N-of-1 deprescribing trial among older men receiving chronic tamsulosin therapy for lower urinary tract symptoms attributed to benign prostatic hyperplasia.
- Trial name
- PERSONAL (NCT05415748)
- Testing
- Tamsulosin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of California, San Francisco
Prostate Hypertrophy, Renal Disease
Effect of Deep BLock on Intraoperative Surgical Conditions
Rationale: A deep neuromuscular block is often associated with improved surgical conditions especially in laparoscopic surgery. However, a deep block comes at the expense of a variety of items that may conflict with the use of a…
- Trial name
- BLISS (NCT01631149)
- Testing
- Surgical block (rocuronium; atracurium/mivacurium)
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Leiden University Medical Center
Benign Prostatic Hyperplasia (BPH)
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS).
- Trial name
- WATER (NCT02505919)
- Testing
- AQUABEAM System, Transurethral Resection of the Prostate (TURP)
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 184 people
- Sponsor
- PROCEPT BioRobotics
Hypogonadism, Benign Prostatic Hyperplasia
TRADE-Testosterone Replacement and Dutasteride Effectiveness
The purpose of this research study is to determine whether the combination of the male hormone testosterone [T] in gel form and the oral drug dutasteride [D], used to shrink large prostate glands can safely reduce the size of the…
- Trial name
- TRADE (NCT00194675)
- Testing
- Dutasteride, Testosterone gel
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- University of Washington
Benign Prostatic Hyperplasia (BPH)
Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia
This is a Phase 4, prospective, open-label, randomized study of Greenlight XPS Laser versus BiVAP Saline Vaporization of the prostate in men with symptomatic Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT01500057
- Testing
- Greenlight XPS Laser, BiVAP Saline Vaporization of the prostate
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Brooklyn Urology Research Group
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Benign Prostatic Hyperplasia
A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as tadalafil in participants with benign prostatic hyperplasia who are being treated with an alpha1 blocker.
- Trial name
- NCT02431754
- Testing
- Tadalafil, Alpha1 Blocker
- Where
- 9 sites in Japan
- Volunteers
- 171 people
- Sponsor
- Eli Lilly and Company